These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 36082726

  • 1. Sodium-glucose Cotransporter-2 Inhibitors in Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes Mellitus: A Meta-analysis.
    Kovil R, Chawla M, Shah T, Sahoo A, Makkar B, Kesavadev J, Seshadri K, Tiwaskar M, Rajput R, Phatak S, Majumdar S, Gupta S.
    J Assoc Physicians India; 2022 Aug; 70(8):11-12. PubMed ID: 36082726
    [Abstract] [Full Text] [Related]

  • 2. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS, Yu AL, Lo HY, Lien CW, Lee JK, Chiang FT, Tu YK.
    Eur J Endocrinol; 2023 Jul 20; 189(1):S17-S25. PubMed ID: 37474112
    [Abstract] [Full Text] [Related]

  • 3. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB, Gul F, Ram P, Kluger AY, Tecson KM, McCullough PA, Rangaswami J.
    Cardiorenal Med; 2020 Jul 20; 10(1):1-10. PubMed ID: 31743918
    [Abstract] [Full Text] [Related]

  • 4. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD.
    JAMA Cardiol; 2021 Jul 01; 6(7):801-810. PubMed ID: 33851953
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: An evidence-based approach to the categories of primary and secondary prevention.
    Mannucci E, Silverii GA.
    Diabetes Obes Metab; 2023 Dec 01; 25(12):3435-3443. PubMed ID: 37529868
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DK, VERTIS CV Investigators.
    Circulation; 2020 Dec 08; 142(23):2205-2215. PubMed ID: 33026243
    [Abstract] [Full Text] [Related]

  • 7. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ, Brunton SA, Rangaswami J.
    Cardiovasc Diabetol; 2023 Nov 16; 22(1):316. PubMed ID: 37974185
    [Abstract] [Full Text] [Related]

  • 8. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
    McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP.
    JAMA Cardiol; 2021 Feb 01; 6(2):148-158. PubMed ID: 33031522
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.
    Circulation; 2019 Apr 23; 139(17):2022-2031. PubMed ID: 30786725
    [Abstract] [Full Text] [Related]

  • 10. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS, Lee JK, Hung CS, Chen WJ.
    Diabetologia; 2021 Dec 23; 64(12):2676-2686. PubMed ID: 34536085
    [Abstract] [Full Text] [Related]

  • 11. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
    Kongmalai T, Hadnorntun P, Leelahavarong P, Kongmalai P, Srinonprasert V, Chirakarnjanakorn S, Chaikledkaew U, McKay G, Attia J, Thakkinstian A.
    Front Endocrinol (Lausanne); 2023 Dec 23; 14():1216160. PubMed ID: 38179304
    [Abstract] [Full Text] [Related]

  • 12. Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials.
    Maddaloni E, Cavallari I, La Porta Y, Appetecchia A, D'Onofrio L, Grigioni F, Buzzetti R, Holman RR.
    Diabetes Obes Metab; 2023 May 23; 25(5):1341-1350. PubMed ID: 36700422
    [Abstract] [Full Text] [Related]

  • 13. Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring.
    Ghosal S, Sinha B.
    Front Endocrinol (Lausanne); 2023 May 23; 14():1168755. PubMed ID: 37469980
    [Abstract] [Full Text] [Related]

  • 14. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.
    Lancet; 2019 Jan 05; 393(10166):31-39. PubMed ID: 30424892
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
    Jang J, Park S, Kim S, Kim SH, Oh YS, Sa YK, Hwang Y, Jang SW, Ihm SH, Choi Y.
    Eur J Prev Cardiol; 2024 Feb 15; 31(3):320-329. PubMed ID: 37798123
    [Abstract] [Full Text] [Related]

  • 16. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
    Usman MS, Siddiqi TJ, Anker SD, Bakris GL, Bhatt DL, Filippatos G, Fonarow GC, Greene SJ, Januzzi JL, Khan MS, Kosiborod MN, McGuire DK, Piña IL, Rosenstock J, Vaduganathan M, Verma S, Zieroth S, Butler J.
    J Am Coll Cardiol; 2023 Jun 27; 81(25):2377-2387. PubMed ID: 37344038
    [Abstract] [Full Text] [Related]

  • 17. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
    Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, Butler J, Cherney DZI, Claggett BL, Fletcher RA, Herrington WG, Inzucchi SE, Jardine MJ, Mahaffey KW, McGuire DK, McMurray JJV, Neal B, Packer M, Perkovic V, Solomon SD, Staplin N, Vaduganathan M, Wanner C, Wheeler DC, Zannad F, Zhao Y, Heerspink HJL, Sabatine MS, Wiviott SD.
    Circulation; 2024 Jun 04; 149(23):1789-1801. PubMed ID: 38583093
    [Abstract] [Full Text] [Related]

  • 18. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Baek JH, Yang YS, Ko SH, Han KD, Kim JH, Moon MK, Park JS, Lee BW, Oh TJ, Chon S, Choi JH, Hur KY.
    Diabetes Metab J; 2022 Sep 04; 46(5):701-712. PubMed ID: 35654585
    [Abstract] [Full Text] [Related]

  • 19. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
    Peng ZY, Yang CT, Kuo S, Wu CH, Lin WH, Ou HT.
    JAMA Netw Open; 2022 Dec 01; 5(12):e2246928. PubMed ID: 36520437
    [Abstract] [Full Text] [Related]

  • 20. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
    Bhattarai M, Salih M, Regmi M, Al-Akchar M, Deshpande R, Niaz Z, Kulkarni A, Siddique M, Hegde S.
    JAMA Netw Open; 2022 Jan 04; 5(1):e2142078. PubMed ID: 34985519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.